Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Change in Accured Expenses (2020 - 2023)

Surgery Partners' Change in Accured Expenses history spans 4 years, with the latest figure at -$1.2 million for Q1 2023.

  • For Q1 2023, Change in Accured Expenses rose 93.33% year-over-year to -$1.2 million; the TTM value through Dec 2023 reached -$1.2 million, up 97.95%, while the annual FY2023 figure was -$1.2 million, 97.95% up from the prior year.
  • Change in Accured Expenses for Q1 2023 was -$1.2 million at Surgery Partners, up from -$4.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $124.7 million in Q2 2020 and bottomed at -$25.1 million in Q4 2021.
  • The 4-year median for Change in Accured Expenses is -$10.4 million (2021), against an average of $166666.7.
  • The largest annual shift saw Change in Accured Expenses crashed 332.76% in 2021 before it skyrocketed 93.33% in 2023.
  • A 4-year view of Change in Accured Expenses shows it stood at -$5.8 million in 2020, then plummeted by 332.76% to -$25.1 million in 2021, then soared by 81.27% to -$4.7 million in 2022, then soared by 74.47% to -$1.2 million in 2023.
  • Per Business Quant, the three most recent readings for SGRY's Change in Accured Expenses are -$1.2 million (Q1 2023), -$4.7 million (Q4 2022), and -$13.5 million (Q3 2022).